Research ArticleArticle
Fevipiprant (QAW039) a slowly dissociating CRTh2 antagonist with the potential for improved clinical efficacy.
David A Sykes, Michelle E Bradley, Darren M Riddy, Elizabeth Willard, John Reilly, Asadh Miah, Carsten Bauer, Simon J Watson, David A Sandham, Gerald Dubois and Steven J Charlton
Molecular Pharmacology February 25, 2016, mol.115.101832; DOI: https://doi.org/10.1124/mol.115.101832
David A Sykes
1 The University of Nottingham;
Michelle E Bradley
2 Novartis
Darren M Riddy
2 Novartis
Elizabeth Willard
2 Novartis
John Reilly
2 Novartis
Asadh Miah
2 Novartis
Carsten Bauer
2 Novartis
Simon J Watson
2 Novartis
David A Sandham
2 Novartis
Gerald Dubois
2 Novartis
Steven J Charlton
1 The University of Nottingham;
Jump to comment:
No eLetters have been published for this article.
In this issue
Molecular Pharmacology
Vol. 105, Issue 4
1 Apr 2024
Research ArticleArticle
Fevipiprant (QAW039) a slowly dissociating CRTh2 antagonist with the potential for improved clinical efficacy.
David A Sykes, Michelle E Bradley, Darren M Riddy, Elizabeth Willard, John Reilly, Asadh Miah, Carsten Bauer, Simon J Watson, David A Sandham, Gerald Dubois and Steven J Charlton
Molecular Pharmacology February 25, 2016, mol.115.101832; DOI: https://doi.org/10.1124/mol.115.101832
Research ArticleArticle
Fevipiprant (QAW039) a slowly dissociating CRTh2 antagonist with the potential for improved clinical efficacy.
David A Sykes, Michelle E Bradley, Darren M Riddy, Elizabeth Willard, John Reilly, Asadh Miah, Carsten Bauer, Simon J Watson, David A Sandham, Gerald Dubois and Steven J Charlton
Molecular Pharmacology February 25, 2016, mol.115.101832; DOI: https://doi.org/10.1124/mol.115.101832
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement